相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The global liposome development and manufacturing services market is projected to grow to $2.34 billion by 2035 at a 9.7% CAGR, driven by increasing demand for drug delivery solutions. - Over 800 clinical trials related to liposomes have been registered to date, with 38% conducted across European clinical sites, highlighting significant therapeutic interest. - Approximately 40% of marketed drugs and 90% of drug candidates under development face solubility and bioavailability issues, creating substantial demand for liposome-based delivery systems. - More than 70 service providers currently offer liposome development and manufacturing services, with therapeutic formulations dominating the market over nutraceutical applications.
- Two major European gene therapy summits are addressing critical analytical and quality control challenges following recent regulatory setbacks, including Rocket Pharma's KRESLADI rejection that exposed CMC vulnerabilities. - The 6th Gene Therapy Analytical Development Summit Europe will bring together 24+ expert speakers and over 90 industry stakeholders to tackle analytics across the gene therapy lifecycle from Pre-IND/IMPD to BLA. - The inaugural Gene Therapy Potency Summit focuses specifically on potency assay challenges during the critical "sweet spot" of drug development from pre-clinical through commercialization. - Both events feature leading companies including Sarepta Therapeutics, Biogen, Sanofi, and regulatory experts from MHRA to provide practical solutions for assay validation and regulatory compliance.
